Charming Medical Limited Class A Ordinary Shares
NASDAQ:MCTAMedical - Care Facilities
+$0.00 today
- Market cap
- $445.55M
- Beta
- 0.00
- P/E (TTM)
- 414.6
- EPS (TTM)
- $0.07
Volume 0.00M
Average 0.87M
MCTA Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Charming Medical Limited Class A Ordinary SharesNASDAQ: MCTA
Depreciation & Amortization · FY2024 · year ended Mar 2025
Depreciation & amortization declines year over year
FY2024 depreciation & amortization of $263.45K fell 32.7% year over year.
Context
- Depreciation & amortization amounted to 4.2% of revenue in FY2024, down 2.3 pp from a year earlier.
- Depreciation & amortization increased in 1 of the last 2 fiscal years.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2024
- 263.45K USD
- Year-over-year change
- -32.7%
- 2-year CAGR
- +11.7%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2024 | 2025-03-31 | 263.45K | -32.7% |
| FY2023 | 2024-03-31 | 391.7K | +85.6% |
| FY2022 | 2023-03-31 | 211.08K | — |
Depreciation & Amortization vs competitors
How MCTA compares with its peers on the latest reported figures
- MCTA's FY2024 depreciation & amortization of $263.45K is the smallest of the 10 companies compared; the peer median is $3.32M.
- Its year-over-year change of -32.7% is the 9th highest of 10, against a peer median of +0.9%.
- Depreciation & amortization amounts to 4.2% of revenue for MCTA, versus a peer median of 1.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $28.51M | +11.8% | +27.6% | 0.5% | |
| LTM Mar 2026 | $15.69M | -14.4% | +10.1% | 1.6% | |
| LTM Mar 2026 | $6.56M | -4.9% | +2.0% | 1.9% | |
| LTM Feb 2026 | $6.47M | -19.3% | +32.0% | 8.0% | |
| LTM Mar 2026 | $3.32M | +1.4% | -6.7% | 2.6% | |
| LTM Mar 2026 | $3.25M | -50.6% | +16.3% | 0.6% | |
| LTM Mar 2026 | $2.17M | +0.9% | +0.9% | — | |
| LTM Mar 2026 | $1.34M | +611.6% | +25.6% | 34.2% | |
| LTM Mar 2026 | $413K | +120.9% | +38.3% | 0.5% | |
MCTACharming Medical Limited Class A Ordinary Shares | FY2024 | $263.45K | -32.7% | — | 4.2% |
| Peer median (excluding MCTA) | $3.32M | +0.9% | +16.3% | 1.7% | |
Competitors are the stored peer set for MCTA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Mar 2023 | FY2023 Mar 2024 | FY2024 Mar 2025 |
|---|---|---|---|
| Net Income | (335.61K) | 821.74K | 1.2M |
| Depreciation & Amortization | 211.08K | 391.7K | 263.45K |
| Deferred Income Tax | 0 | 62.48K | 134.87K |
| Stock-Based Compensation | 0 | 0 | 0 |
| Change in Working Capital | 2.5M | (943.05K) | (1.16M) |
| Accounts Receivables | (154.02K) | (164.98K) | (44.29K) |
| Inventory | (55.87K) | 38.18K | 1.35K |
| Accounts Payables | 180.4K | 210.28K | (204.69K) |
| Other Working Capital | 2.53M | (1.03M) | (913.02K) |
| Other Non-Cash Items | 60.9K | (37.45K) | (10.89K) |
| Operating Cash Flow | 2.43M | 295.43K | 425.89K |
| Capital Expenditures | (606.19K) | (210.6K) | (287.53K) |
| Acquisitions (Net) | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | (1.94M) |
| Sales of Investments | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 |
| Investing Cash Flow | (606.19K) | (210.6K) | (2.23M) |
| Debt Repayment | (177.92K) | (115.85K) | 48.93K |
| Common Stock Issued | 0 | 0 | 0 |
| Common Stock Repurchased | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 |
| Other Financing Activities | (1.25M) | 216K | 472.37K |
| Financing Cash Flow | (1.43M) | 100.15K | 521.3K |
| Effect of Forex Changes | 5.66K | (10.51K) | (4.62K) |
| Net Change in Cash | 402.99K | 174.46K | (1.29M) |
| Free Cash Flow | 1.83M | 84.83K | 138.36K |
Charming Medical Limited Class A Ordinary Shares
NASDAQ:MCTA
Intrinsic Alpha fair value
Locked
Current Price
$29.36
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.